OraSure Technologies Q3 revenue rises, gross margin improves

Overview

• US diagnostics and sample management firm's Q3 revenue rose 14% yr/yr

• Q3 gross margin improved to 45.2% from 43.5% a year ago

• Q3 adjusted operating loss narrowed compared to last year

Outlook

• Company guides Q4 2026 revenue between $30 mln and $32 mln

• Company expects full-year 2026 revenue growth of 4.7% at midpoint

Result Drivers

• DIAGNOSTICS GROWTH - Co said higher HIV and HCV revenues and new Sickle SCAN sales drove diagnostics revenue increase

• SAMPLE MANAGEMENT - Growth in key commercial customers and order timing boosted sample management revenue

• OPERATIONAL EFFICIENCY - Improved operational efficiency led to higher gross margin, partially offset by product mix

Company press release:

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for OraSure Technologies Inc is $5.50, about 59.9% above its November 6 closing price of $3.44

Reuters Recommended Reads

• Nov 9 - Orthofix Medical Q3 revenue misses; cuts full-year guidance due to weaker US Spine performance

• Nov 9 - Medical tech firm NeurAxis' Q3 revenue jumps on broader insurance coverage

• Nov 6 - bioAffinity Technologies Q3 revenue falls on lower reimbursement

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)